Regenxbio has guided its Duchenne muscular dystrophy (DMD) gene therapy candidate through another test, reporting a clean ...

An assessment of a drug for a rare muscular condition was removed from the website of the National Centre for Pharmacoeconomics, at the request of the Department of Health.

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

The selected dose in the pivotal phase is lower than for other drug candidates in clinical trials or gene therapy drugs for Duchenne.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA ...

Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low ...

For more information, please visit www.nmdpharma.com.

The MarketWatch News Department was not involved in the creation of this content. PARAMUS, N.J., March 9, 2026 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma, New Jersey, USA; President, Yukiteru Sugiyama ...